Please login to the form below

Not currently logged in
Email:
Password:

FDA strengthens safety warnings for Lipitor, Crestor, Zocor

Label update for several statins includes risk of diabetes and memory loss

The US Food and Drug Administration (FDA) has updated the labels of several statins to reflect an increased risk of diabetes and memory loss.

The affected cholesterol-lowering medications include Pfizer's Lipitor (atorvastatin), AstraZeneca's Crestor (rosuvastatin) and Merck & Co's Zocor (simvastatin).

Labels have been revised to reflect data from studies that patients being treated with statins "may have a small increased risk of increased blood sugar levels and of being diagnosed with type 2 diabetes mellitus".

Cognitive effects have also been reported with statin use, with labels updated to include information about some patients experiencing memory loss and confusion, although the FDA said these reports generally have "not been serious" and that discontinuing statin use reversed any symptoms.

As well as these extra warnings, the labels have also been revised to remove the need for routine monitoring of liver enzymes in patients using the drugs.

Early clinical trials had indicated possible liver damage related to statin use, and the FDA initially advised healthcare professionals to regularly test their patients' liver enzyme levels.

However, the agency has now said that serious liver injury with statins is "rare and unpredictable" in individual patients, with routine monitoring ineffective in preventing the side effect.

Liver enzyme tests are now recommended before starting statin therapy, with follow-up tests only necessary if there are symptoms of liver damage.

Others statins to be affected by label updates are Lescol (fluvastatin), Mevacor (lovastatin), Altoprev (lovastatin extended-release), Livalo (pitavastatin) and Pravachol (pravastatin).

Certain combination products involving the affected medicines have also had their labels updated and there was an additional update to the label of Merck's Mevacor to clarify the risk of muscle injury and advise on contraindicated drugs, such as certain HIV treatments.

Dr Amy Egan, deputy director for safety in FDA's division of metabolism and endocrinology products (DMEP), said these warnings shouldn't prevent patients from using the products

She said: “The value of statins in preventing heart disease has been clearly established. Their benefit is indisputable, but they need to be taken with care and knowledge of their side effects.”

29th February 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you in the world of the patient...

Latest intelligence

RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
What do Healthcare Professionals think about the inclusion of remote selling techniques?
Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...

Infographics